Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis

Craig D Fisher1, Jonathan P Jackson, Andrew J Lickteig

  • 1Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, 1703 East Mabel, Tucson, AZ 85721, USA. cfisher@pharmacy.arizona.edu

Insights

Non-alcoholic steatohepatitis (NASH) alters drug metabolism by increasing pregnane X receptor (PXR) and NAD(P)H:quinone oxidoreductase 1 (Nqo1) levels. However, induction of other drug-metabolizing enzymes remains largely unaffected in this disease model.

Area of Science:

  • Pharmacology
  • Hepatology
  • Biochemistry

Background:

  • Non-alcoholic steatohepatitis (NASH) impairs liver function and drug metabolism.
  • Xenobiotic-activated transcription factors (AhR, CAR, PXR, PPARalpha, Nrf2) regulate drug-metabolizing enzymes (DMEs).

Purpose of the Study:

  • To investigate how experimental NASH affects xenobiotic transcription factor activation.
  • To determine the impact of NASH on downstream DME induction.

Main Methods:

  • Mice were fed a methionine-choline-deficient (MCD) diet to induce NASH.
  • Mice were treated with specific inducers for AhR, CAR, PXR, PPARalpha, and Nrf2.
  • mRNA levels of transcription factors and DMEs (Cyp1A1, Cyp2B10, Cyp3A11, Cyp4A14, Nqo1) were analyzed.

Main Results:

  • Hepatic PXR mRNA levels increased significantly in MCD diet-fed mice.
  • MCD diet did not alter inducibility of Cyp1A1, Cyp2B10, Cyp3A11 by their inducers.
  • Constitutive Cyp4A14 mRNA increased, but further induction by clofibrate was not observed.
  • Hepatic Nqo1 mRNA increased with the MCD diet, and further induction by oltipraz was possible.

Conclusions:

  • Experimental NASH significantly upregulates hepatic PXR and constitutive Cyp4A14 and Nqo1 mRNA levels.
  • The inducibility of key drug-metabolizing enzymes Cyp1A1, Cyp2B10, and Cyp3A11 by their respective activators is not compromised by NASH.
  • NASH affects Nqo1 expression, but its inducibility by Nrf2 activators remains intact.

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...